Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ReNeuron has decided to advance its Pisces Phase I clinical trial to evaluate a higher dose of ReN001 with the recommendation of an independent Data Safety Monitoring Board (DSMB).
Subscribe to our email newsletter
ReN001 is a stem cell therapy for disabled stroke patients.
The recommendation was based on the review of safety data from the first dose cohort of three patients treated with ReN001.
ReNeuron CEO Michael Hunt said they are delighted that the DSMB have given a favorable recommendation to proceed to a higher dose in the PISCES stroke trial.
"This represents an important milestone for the trial and the preliminary data from the trial also add value to our other therapeutic programmes using the CTX neural stem cell line that forms the basis of the ReN001 stroke treatment," Hunt said.
"We look forward to providing further updates on the PISCES clinical trial in due course."